Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulbactam + ceftazidime versus cefoperazone-sulbactam for carbapenem-resistant Acinetobacter baumannii HABP/VABP
ChiCTR1900024825Phase 4Recruiting
- Sponsor
- Yongchuan Hospital Affiliated to Chongqing Medical University
- Start
- Aug 2019
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sulbactam, ceftazidime, cefoperazone + sulbactam and doxycycline in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and Acinetobacter baumannii infection (2 arms), sponsored by Yongchuan Hospital Affiliated to Chongqing Medical University. Primary endpoint: Clinical cure at test of cure. Started Aug 2019; status: recruiting.
02
Drugs
sulbactamceftazidimecefoperazone + sulbactamdoxycycline
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Acinetobacter baumannii infection
Beyond the preview
Go deeper on ChiCTR1900024825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024825.